Aventis to sell Azmacort to Kos Pharmaceuticals
Aventis has agreed to sell the global rights to Azmacort (triamcinolone acetonide) Inhalation Aerosol to Kos Pharmaceuticals, a speciality pharmaceutical company based in Miami, Florida, for a one-time cash payment of US$200m.
Aventis has agreed to sell the global rights to Azmacort (triamcinolone acetonide) Inhalation Aerosol to Kos Pharmaceuticals, a speciality pharmaceutical company based in Miami, Florida, for a one-time cash payment of US$200m.
Additionally, on the launch of an Azmacort HFA formulation (using hydrofluoralkane propellant), Kos will pay Aventis an annual royalty on net sales.
The divestiture of this product is in line with Aventis's strategy to evaluate its product portfolio and assess opportunities for divestment and replacement with compounds focused on strengthening key disease areas. The deal is expected to be completed by the end of the first quarter of 2004, pending US regulatory approval.
Azmacort is an inhaled corticosteroid indicated as prophylactic treatment for the maintenance of asthma. In 2003, global net sales of Azmacort were approximately €78m.